- Home
- NNBR vs MOLN Comparison
NNBR vs MOLN Comparison
Compare NNBR & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- MOLN
- Stock Information
- Founded
- NNBR 1980
- MOLN 2004
- Country
- NNBR United States
- MOLN Switzerland
- Employees
- NNBR N/A
- MOLN N/A
- Industry
- NNBR Industrial Machinery/Components
- MOLN
- Sector
- NNBR Industrials
- MOLN
- Exchange
- NNBR Nasdaq
- MOLN Nasdaq
- Market Cap
- NNBR 129.3M
- MOLN 142.6M
- IPO Year
- NNBR 1994
- MOLN 2021
- Fundamental
- Price
- NNBR $2.51
- MOLN $3.58
- Analyst Decision
- NNBR
- MOLN Hold
- Analyst Count
- NNBR 0
- MOLN 1
- Target Price
- NNBR N/A
- MOLN $4.00
- AVG Volume (30 Days)
- NNBR 72.7K
- MOLN 5.0K
- Earning Date
- NNBR 10-29-2025
- MOLN 11-05-2025
- Dividend Yield
- NNBR N/A
- MOLN N/A
- EPS Growth
- NNBR N/A
- MOLN N/A
- EPS
- NNBR N/A
- MOLN N/A
- Revenue
- NNBR $433,709,000.00
- MOLN $856,302.00
- Revenue This Year
- NNBR N/A
- MOLN N/A
- Revenue Next Year
- NNBR $4.88
- MOLN $1,000.00
- P/E Ratio
- NNBR N/A
- MOLN N/A
- Revenue Growth
- NNBR N/A
- MOLN N/A
- 52 Week Low
- NNBR $1.58
- MOLN $3.36
- 52 Week High
- NNBR $4.67
- MOLN $7.60
- Technical
- Relative Strength Index (RSI)
- NNBR 57.36
- MOLN 46.94
- Support Level
- NNBR $2.41
- MOLN $3.54
- Resistance Level
- NNBR $2.63
- MOLN $3.86
- Average True Range (ATR)
- NNBR 0.13
- MOLN 0.21
- MACD
- NNBR 0.00
- MOLN -0.01
- Stochastic Oscillator
- NNBR 69.23
- MOLN 8.27
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.